ArticleEndocrine pathology1998
Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.
Article in Endocrine pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Genetic aspects of pituitary carcinoma: A systematic review.Medicine · 2016Pooled it
- Trial
- Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.Immunity, inflammation and disease · 2024Review
- Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.Frontiers in endocrinology · 2021Review
- An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.Endocrine pathology · 2019Article
- Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review.Frontiers in oncology · 2018Article
- Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.Current opinion in endocrinology, diabetes, and obesity · 2017Review
- ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.Endocrinology · 2015Article
- Expression and function of ErbB receptors and ligands in the pituitary.Endocrine-related cancer · 2011Review
- HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Heregulin regulates prolactinoma gene expression.Cancer research · 2009Article
- Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.Pituitary · 2009Review
- Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy.Journal of neuro-oncology · 2008Article
- Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics.Journal of neuro-oncology · 2007Article
- Pituitary tumors: prognostic indicators.Endocrine · 2005Review
- Pituitary carcinoma: diagnosis and treatment.Endocrine · 2005Review
- Pituitary carcinoma: report of an exceptional case and review of the literature.Journal of endocrinological investigation · 2002Review
- Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece.Endocrine pathology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary carcinomas are very rare neoplasms with a poor prognosis. We report a case of Cushing's disease resulting from a pituitary carcinoma in a 22-yr old female, who died of massive hepatic failure. At autopsy, there was invasion of the parasellar structures and vasculature by the tumor, which stained positively only for ACTH. There were two metastatic nodules in the liver, which also stained positively for ACTH. When compared to other cases of Cushing's disease (n = 52), other pituitary adenomas (n = 292). and normal pituitary tissues (n = 21), the pituitary carcinoma was the only one with c-erbB-2 membrane staining in both the sellar-located tissue and liver metastasis. C-erbB-2 staining was present in the cytoplasm of a variable number of cells in 40% of the invasive adenomas (n = 103), while only 1.2% of the noninvasive tumors (n = 241) expressed this protein (p < 0.001). No particular immunohistological type preferentially expressed this protein. In normal pituitary tissues, 10% of the cells expressed cytoplasmic c-erbB-2. A higher index of proliferating cell nuclear antigen (PCNA) in the primary tumor and liver metastasis (10%) was also found compared to other ACTH-secreting adenomas (invasive, 3.4 -t 1 S% vs 1 ii +/- 1.5% in noninvasive) and other pituitary tumors (invasive, 2.9 +/- 1.5% vs 1.5 +/- 1.3% in noninvasive). The PCNA index was significantly higher in invasive tumors than in noninvasive adenomas (p = 0.004). PCNA staining was negative in normal pituitary tissues. Staining for p53, pRB and p(2ras) was negative in the carcinoma and liver metastasis. We suggest that the c-erbB-2 membrane pattern and a higher PCNA index may indicate a worse prognosis in adenohypophyseal neoplasia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.